Plain-English translation of NCT07598370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing an experimental medication called to see how it affects certain proteins found in your spinal fluid that are linked to Alzheimer's disease. Researchers want to understand whether this medication changes these biomarkers—measurable signs of disease in the body—which could help them learn whether the treatment is working. The medication is given by IV infusion, and the study lasts about 9 months with monthly visits.
Alzheimer's disease is a progressive condition that affects memory and thinking, and current treatments are limited. By studying how this medication affects specific biomarkers in spinal fluid, researchers hope to gain early insight into whether this new approach could slow or help manage the disease.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic about once a month for approximately 9 months. At these visits, you would receive intravenous infusions of the medication and undergo routine monitoring including blood tests and MRI scans. You would also have a spinal tap (lumbar puncture) to collect cerebrospinal fluid so researchers can measure the biomarkers they are studying. Your study partner would help track any changes in your memory or thinking during this time.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States
Australia